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Abstract  
 
Current data indicate that the ‘bronchiolitis’ diagnosis comprises more than one condition. 
Clinically, pathophysiologically and even genetically three main clusters of patients can be 
identified among children suffering from severe bronchiolitis (or first wheezing episode): 1) 
Respiratory syncytial virus (RSV) -induced bronchiolitis, characterized by young age of the patient, 
mechanical obstruction of the airways due to mucus and cell debris and increased risk of recurrent 
wheezing. For this illness an effective prophylactic RSV-specific monoclonal antibody is available. 
2) Rhinovirus -induced wheezing, associated with atopic predisposition of the patient and high risk 
for subsequent asthma development, which may, however, be reversed with systemic 
corticosteroids in those with severe illness. 3) Wheeze due to other viruses, characteristically likely 
to be less frequent and severe. Clinically, it is important to distinguish between these partially 
overlapping patient groups as they are likely to respond to different treatments. It appears that the 
first episode of severe bronchiolitis in under 2-year-old children is a critical event and an important 
opportunity for designing secondary prevention strategies for asthma. As data have shown 
bronchiolitis cannot simply be diagnosed using a certain cut-off age, but instead, as we suggest, 
using the viral etiology as the differentiating factor.  
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Abbreviations 
 
AdV adenovirus 
BoV bocavirus 
CDHR3 cadherin related family member 3 
DC dendritic cell 
Eos eosinophil 
Flu influenza virus 
GWAS genome-wide association studies 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
ILC innate lymphoid cell 
MDA melanoma differentiation-associated protein 
MoAb monoclonal antibody  
moDC monocyte-derived dendritic cells 
NK natural killer cell 
n-3 LCPUFA omega-3 long-chain polyunsaturated fatty acid 
OCS oral corticosteroid 
PIV parainfluenza virus 
RIG retinoic acid inducible gene 
RSV respiratory syncytial virus 
RV rhinovirus 
TCE3 third T-cell receptor 
Th T helper 
TLR toll-like receptor 
TSLP thymic stromal lymphopoietin 
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Introduction 
 
Bronchiolitis is most often described as a virus-induced inflammation of small bronchioles and their 
surrounding tissue. According to different guidelines, its upper age limit varies from 6 or 12 
months, 12 months being preferred by many European countries, to 2 years, used in the U.S.
1,2,3
 
Clinically, bronchiolitis is characterized by expiratory breathing difficulty in infants. Other 
symptoms include cough, tachypnea, hyperinflation, chest retraction, widespread crackles and 
wheezing. Wheezing is generally not a mandatory criterion. Instead it is a descriptive term, defined 
as a whistling sound during expiration, often accompanied by dyspnea. It can be caused by 
obstruction at any level of the lower airways. However, when bilateral/polyphonic, inflammation is 
probable.  
 
Bronchiolitis presents a huge clinical burden. Depending on the definitions, the prevalence of 
bronchiolitis has been between 18-32% in the first and 9-17% in the second year of life.
2,3
 At the 
same time, the overall risk of recurrent wheezing and asthma is 70% before school-age and  50% 
during schoolyears.
1,4
 However, patient characteristics and the risk of asthma strongly vary inside 
the bronchiolitis cohort thus revealing different disease entities, some of which have a markedly 
high risk of subsequent asthma development. 
 
To that end, we propose a differentiation of bronchiolitis subtypes by specific viruses and a broad 
inclusion of children by extending the upper age limit from 6 or 12 months up to 2 years Recent 
data clearly indicate that the two major viral causes of bronchiolitis, respiratory syncytial virus 
(RSV) and rhinovirus (RV), have distinct genetics, pathogenetic mechanisms, clinical 
characteristics and responses to treatments both regarding short and long-term outcomes.
1,5-7 
Thus, a 
general bronchiolitis diagnosis should be revisited, as the identification of different viruses 
associated with severe bronchiolitis should improve our understanding of the disease and open 
avenues for precision medicine. 
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Etiology and risk factors 
 
By definition bronchiolitis is a virus infection, and PCR diagnostics has reached a 100% virus 
detection rate in severe bronchiolitis.
8
 RSV is the most important causative agent of bronchiolitis 
during infancy, and it has been detected in 50-80% of the hospitalized bronchiolitis cases (Fig. 
1).
9,10
 RV is the second most common viral agent of bronchiolitis during infancy but it starts to 
dominate virus detection after 12 months (Fig. 1). The next most common viruses in connection to 
broncliolitis are human bocavirus and human metapneumovirus followed by parainfluenza virus, 
adenovirus, coronavirus and influenza virus (Fig. 1). Virus coinfections, mostly with RSV and RV, 
occur in 10-40% of the severe cases, but reports on their clinical significancy are inconclusive.
9,10
 
 
RSV belonging to the Pneumovirus genus in the Paramyxoviridae family, is an enveloped single 
stranded RNA virus with two antigenically different A and B subtypes with 11 and 23 genotypes, 
respectively.
11
Although severe reinfections have been reported in young children, they are generally 
mild.
12
 Main risk factors for RSV-bronchiolitis include prematurity, chronic lung disease (low lung 
function), congenital heart disease, other underlying medical conditions and young age (1-6 months 
of age), i.e. conditions in which excessive mucus inthe airways is problematic, as well as deficient 
interferon responses.
2
 
 
RV belonging to the Enterovirus genus in the Picornaviridae family is a nonenveloped single-
stranded RNA virus and it comprises a genetically diverse group of viruses. It has three distinct 
subgroups, A-, B- and C, which consist of 83, 32 and 55 genotypes, respectively.
1,13
 This antigenic 
diversity presents a major challenge when establishing protective immunity and developing 
vaccines.
14
 Risk factors for RV induced bronchiolitis include T helper 2 polarized immune 
responses, allergen exposure, impaired epithelial barrier, deficient interferon responses and 
diminished lung function.
1,15
 
 
Clinical characteristics 
 
Acute bronchiolitis is a clinical diagnosis that requires epidemiological and virological data. In 
infants,  few days of runny nose, fever and cough typically precede the signs of lower respiratory 
distress (nasal flaring, tachypnoea and subcostal recessions) (Fig. 2).
1,2
  In such a case, respiratory 
crackles are suggestive of RVS etiology whereas bilateral wheezing is suggestive of RV etiology.
16
  
A plethora of other respiratory sounds can also be heard. 
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Most infants with bronchiolitis present a mild clinical form that usually resolves in one to two 
weeks and can be safely managed at home by well instructed parents. Adequate information 
conserning the signs of deterioration (including low oxygen saturations) and the need for urgent 
transfer to hospital is of critical importance. 
 
It is still not clear whether the type of virus detected in the nasopharynx could determine the degree 
of severity of the infection. Most often RSV infection has been linked to more severe “non-wheezy” 
bronchiolitis, need for possible intensive care unit admission and prolonged duration of stay.
17,18
 
However, in 2002 a Greek case-control study showed that RV detected in the upper airways could 
be strongly associated with episodes of increased severity.
19
 Other viruses have been less often 
linked to severe illness. 
 
Since the early 1990’s there have been several efforts towards developing clinical severity scoring 
tools for bronchiolitis. From the Severity Scoring Tool to Tal and modified-Tal scoring tools, there 
have been several instruments validated and used both in research and in clinical management 
settings.
20,21
 However, there is no tool developed to assess both clinical severity and quality of life 
parameters for these children. 
 
 
Apart from using merely clinical severity scores, attempts have been made in order to cluster acute 
bronchiolitis by phenotype. In 2016, four such phenotypes were introduced in two large multicenter 
studies: Profile A was characterized by RV etiology, history of wheezing, wheezing at presentation, 
eczema and older age of the patient; profile B by RSV etiology, wheezing at presentation, but no 
history of wheezing or eczema; profile C was the most severely ill group, with a longer hospital stay 
and high probability of RSV infections and intensive care unit treatments; and profile D had the 
least severe illness, including non-wheezing children with a shorter length of hospitalization.
18
 The 
heterogeneity apparent in the clinical profiles of the patients highlight the need for a more 
personalized approach in the diagnostics and management of this condition.  
 
Genetics 
 
While RSV and RV are both common environmental exposures, is severe bronchiolitis relatively 
rare. It therefore seems likely that other host factors than viruses, such as genetics, are important 
risk factors as well. Unfortunately, the current understanding of bronchiolitis genetics is rather 
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limited in this respect. A twin study estimated the heritability of RSV bronchiolitis to be only 
16%,
22 
where as the estimated heritability of asthma is more than 50%.
23
 
 
At present, genome-wide association studies (GWAS), including replication of identified loci, is the 
prefered method for gene discovery, but only one, relatively small, GWAS of bronchiolitis has been 
performed without genome-wide significant findings.
24
 A number of susceptibility genes have been 
suggested from candidate gene studies. Most studies focused on RSV-bronchiolitis and the reported 
associations include genes related to immune regulation and surfactant proteins.
25
 Several of these 
genes have also been associated with asthma,
25
 suggesting that the association between RSV-
bronchiolitis and later asthma development might partly be explained by shared genetics.
1,18
 
 
Nevertheless, bronchiolitis is a poorly defined and highly heterogeneous disease entity with 
variability in clinical presentation, age at infection, and triggering factors, as well as in the 
underlying genetic mechanisms. For example, it would be expected that RV-bronchiolitis in older 
children,
18
 a phenotype also characteriz d by a higher risk of asthma predisposition, would also 
have a higher degree of shared heritability with asthma. 
 
The strongest asthma locus discovered to date, 17q21, hass also been found to be associated with 
wheezing during the early years of life.
26
 Furthermor , there is an interaction to be found between 
this locus and early wheezing in relation to the risk of later asthma. Wheezing episodes during the 
early years of life are a much stronger risk factor for asthma in children with 17q21 risk variants 
than in children without it, and this seems more pronounced for episodes triggered by RV than 
RSV.
26
 
 
Another asthma gene with a putative role in connection to bronchiolitis is the cadherin-related 
family member 3 (CDHR3). This gene was first discovered as a susceptibility gene for early 
childhood asthma with recurrent severe exacerbations.
27
 Only later was it suggested from 
experimental studies that CDHR3 also functions as an RV-C receptor.
28 
This was subsequently 
confirmed clinically in the COPSAC and COAST birth cohort studies where the CDHR3 risk 
variant was specifically associated with early life respiratory episodes triggered by RV-C.
29
 In line 
with this, in a meta-analyses of CDHR3 polymorphism in relation to bronchiolitis found an 
association was found with non-RSV bronchiolitis, which is likely to be triggered by RV, while 
there was no association with RSV bronchiolitis.
30
 Thus, CDHR3 gene variation could partly 
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explain bronchiolitis heterogeneity by being associated with a phenotype characterized by recurrent 
RV infections but not with phenotypes triggered by RSV or other viruses. 
 
Genetic studies might help us in understanding the functional and clinically more relevant subtypes 
of bronchiolitis and provide basis for the targeted prevention of asthma. For this reason, future 
studies should be powered toward genome-wide association analyses that are not limited by current 
knowledge and could therefore allow for the identification of unexpected risk genes and novel 
disease mechanisms. Optimally, such studies should include various clinical presentations and 
assessment of viral triggers in order to elucidate subtype-specific mechanisms. 
 
Microbiome  
 
The complex communities of microbes inhabiting all parts of the human body are collectively 
termed the microbiome. This immense microbial environment has the potential for stimulating the 
developing immune system,
31
 as well as act as a disease modifier. The link between microbiome 
and susceptibility to bronchiolitis and subs quent asthma has been explored both regarding the 
airway and the gut microbiome, but the mechanisms behind the possible effects remain to be fully 
understood. 
 
As it comes to the microbiome of the airways, a diverse microbiological continuity exists between 
upper and lower airways..
32
 The dramatic development of the microbiome of the airways begins at 
birth and is influenced by factors such as siblings, day-care attendance, antibiotics and prior 
infections (Fig. 3).
 33,34
 It has been speculated whether this low biomass compartment will obtain a 
steady colonization pattern over time. Recent studies have suggested that certain microbial 
colonization patterns prevalent already in early childhood may affect the risk of bronchiolitis and 
precede the development of persistent wheeze or asthma.
35
 Furthermore, the severity of the acute 
respiratory infections may be modulated by the type of microbial community in the airways 
independent of RSV or RV co-infection, while at the same time, both RSV and RV may increase 
the severity of the infection independent of the bacteria.
34
 It has also been shown that antibiotic 
treatment during acute wheezing episodes in childhood greatly decreases the duration of the 
symptoms, thus pointing toward microbial effects.
36
 Likewise, a study of 1005 infants demonstrated 
that certain airway microbiota profiles seemed to increase the severity of bronchiolitis.
37
 The rate of 
intensive care use and the length of hospital stay during the episode of acute bronchiolitis was 
particularly high in infants with a Haemophilus-dominant profile but low in infants with a 
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Moraxella-dominant profile. This, although low in statistical power, was especially apparent in 
children with RSV bronchiolitis but not found for RV bronchiolitis. In a small randomized trial of 
40 children hospitalized with RSV bronchiolitis, treatment with azithromycin during the acute 
episode seemed to alleviate the subsequent risk of long-term respiratory morbidity.
38
 
 
The microbiome of the human gut is shaped by an extensive ongoing maturation processes over the 
first years of life. It undergoes rapid development,
39
 while at the same time providing vast 
stimulation for the child’s developing immune system during a period when these encounters may 
be critical for the training of the adequate immune responses.
31
 The composition of the microbiome 
is shaped by the environmental encounters in early life and can be altered or perturbed by factors 
such as antibiotics, delivery mode and diet.
40
 A recent study demonstrated that children with a 
delayed microbial maturation of the gut microbiome during the first year of life had a markedly 
increased risk of recurrent wheezing and later asthma.
39
 Conversely, an adequate microbial 
maturation during this period seemed to protect the children, pointing toward possible future 
preventive measures against childhood respiratory morbidity through manipulation of the 
microbiome in early life. 
 
Pathogenesis   
 
Although RSV and RV viruses, like respiratory viruses in general, are transmitted via direct contact 
or aerosol particles and replicate in epithelial cells of the airways, show RSV and RV infections 
various common as well as distinct pathogenic mechanisms. Typically, as a result of innate immune 
activation, an early burst of type I/III interferons will occur rapidly after respiratory viral infection. 
This will be followed by an induction of cytokines, including alarmins, chemokines and growth 
factors that activate and attract innate lymphoid cells, granulocytes, dendritic cells and monocytes 
to the site of infection.
1,41,42
 The combined effect of the virus and the inflammatory response leads 
to epithelial cell apoptosis, necrosis and epithelial sloughing, as well as mucus overproduction. 
However, while RSV infections can lead to severe lower respiratory tract infection primarily in very 
young children, tend RV infections to result in severe wheezing in slightly older children, those 
with atopic predisposition in particular.
1
 In order to understand these differences, we need a better 
insight into the immunological events in the lungs in as a response to these early respiratory 
infections.
42,43
 
 
RSV infections 
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The initial response of the mucosa to RSV infection is a strong induction of antiviral type I and III 
interferons and interferon induced genes (Fig. 4A). As RSV has developed potent mechanisms to 
evade this innate interferon response, is the virus able to infect most infants through RSV-NS1/2 
proteins inhibiting IRF-3 and STAT-2 reducing both IFN-I and -III responses and RSV-F protein 
suppressing IRF-1 through EGRF activation.
44-47
 While severe RSV bronchiolitis is associated with 
weaker antiviral innate interferon responses, are data on the association between virus genome load 
and illness severity discrepant.
47-48
 
 
Furthermore, ineffective inflammatory and adaptive immune responses are important factors that 
contribute to severe RSV disease. As at birth the immune system is still immature and needs to 
develop, it depends mostly on the innate immune system in response to toll-like receptor (TLR) 
ligation and maternal-derived antibodies. At the same time pro-inflammatory innate immune 
responses are not very prominent as anti-inflammatory cytokines, like interleukin (IL) -10 and 
transforming growth factor (TGF) -beta, prevail since during pregnancy mother’s immune system 
protects the fetus.
49
 As a consequence, T h lper (Th)1 cell skewing cytokines like IL-12 seem to 
develop rather slowly in young infants, even in the presence of TLR ligating viruses and increased 
type I interferon production.
50,51
 Interestingly, the cytokines IL-6 and IL-23, both potent inducers of 
IL-17 producing T cells, were found to be increased in TLR-stimulated neonatal cells and neonates 
were shown to have increased numbers of Th17 cells (Fig. 4A).
52
 As enhanced pathology following 
RSV infections is often associated with increased IL-17 production and this cytokine is more 
prominent in neonates, the presence of this cytokine may contribute to a more severe disease 
state.
53,54
 In addition, studies in neonatal mice have shown that there is a spontaneous early wave of 
innate cytokines like IL-33, a Th2 skewing cytokine, and a recruitment of innate lymphoid cells 
(ILC) -2 into the lungs that reaches the maximum at day 14 after birth.
55,56
  
 
Therefore, age-specific events in neonatal lungs seem to naturally support the initial development of 
Th2 immune responses that combined with a yet ineffective activation of innate immunity and IL-17 
being upregulated in young infants, drive mucus hyperproduction and the promotion of severe 
pathology during early RSV infections.
57
 In addition, B cell function is not yet developed in very 
young infants (<6 months of age) and it takes more time to generate a sufficient and sustained 
antibody production. As at very early phase, babies still rely on maternal antibodies, are babies born 
from a mother with high circulating neutralizing antibodies better protected from severe diseases.
58
 
This notion has led to the idea of developing a vaccine for RSV that targets pregnant mothers 
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instead of young children. Thus through vaccinating the mothers the children would be provided 
with an increased transfer of protective maternal antibodies against RSV.
59,60
   
 
RV infections 
 
Rhinoviruses also target directly airway epithelial cells. RV type A frequently causes lower 
respiratory tract infection, and RV type C in particular is linked to severe wheezing in infected 
children.
8,13,61
 The increased risk of severe RV infection with wheeze in young children with a 
strong family history of allergy and asthma may be explained by a partial defect in mucosal anti-
viral innate interferon responses, due potentially to early allergic airways inflammation (Fig. 4B). 
The airway mucosa of asthmatics, who have allergic airway inflammation, has been shown to be 
associated with reduced type I and III interferon responses.
62,63 
To understand the particularly high 
pathogenic potential of RV-C it is important to note that CDHR3 has recently been identified as a 
unique receptor for RV-C.
18
 Interestingly, a polymorphism in the CDHR3 gene (resulting in a 
higher expression of CDHR3 on the epithelial surface) was associated with the increased risk of 
childhood asthma.
27
 RV-C has also evolved specific molecular tools to reduce IFN-β expression 
and downstream signaling in airway epithelial cells,
64
 which may possibly explain the more severe 
course of respiratory RV-C infections. In addition, RV infections of airway epithelial cells are 
strong inducers of type 2 innate cytokines, like IL-25 and IL-33, which subsequently initiate or 
boost type 2 immunity in the lungs via IL-5 and IL-13 producing innate lymphoid cells (ILC) 2 and 
Th2 cells (Fig. 4B). Surprisingly, the induction of innate cytokines by RV infections was stronger in 
airway epithelial cells from asthmatics compared to healthy controls.
65
 Also, the induction of type 2 
innate cytokines may be more pronounced during early childhood, as compared to adult mice, 
human rhinovirus infections in neonatal mice showed more pronounced IL-13 and IL-25 
expression, mucus secretion and airway hyperresponsiveness.
66
 This process may be further boosted 
or co-inciding by an early spontaneous wave of IL-33-dependent type 2 cytokines and cells in 
developing lungs of neonatal mice.
55,56
 Overall, although RV infections are linked to the induction 
of milder epithelial inflammation than RSV infections, they tend to reduce type I IFN expression 
and cause inflammation with Th2 cell characteristics, disrupted tight junction expression and high 
cytokine levels that promote bronchospasm, oedema and mucus production and lead to airway 
obstruction and wheeze.
1,41
  
 
Treatment  
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Substantial knowledge gaps and controversies exist in the management of acute bronchiolitis. Most 
guidelines recommend primarily supportive treatment, i.e. oxygen, nasal suctioning, mechanical 
ventilation and hydration.
67 
High flow oxygen therapy using nasal cannula has shown promising 
results.
68
 There is conflicting information across clinical guidelines about the role of nebulized 
hypertonic saline in acute management of bronchiolitis. Only a few current guidelines recommend 
bronchodilators.
2
 Overall, corticosteroids (see details below), nebulized epinephrine or antibiotics 
are not recommended.
2
 Because of the current frustration with the existing treatment modalities 
(high use of bronchodilators, antibiotics and corticosteroids) and as the majority of the previous 
trials have not been based on virus specific data, is further research required in order to direct focus 
to more personalized management plans in the treatment of acute bronchiolitis.
69
 
 
Treatment for RSV 
 
Palivizumab: Immunoprophylaxis with palivizumab, a humanized monoclonal antibody against the 
RSV F glycoprotein, decreases the risk of hospitalization due to severe RSV illness among preterm 
infants (72% reduction), those with chronic lung disease (65% reduction) and hemodynamically 
significant congenital heart disease (53% reduction).
60
 Interestingly, palivizumab has effectively 
reduced recurrent wheezing following hospitalization due to RSV, but not asthma.
70
 
 
Ribavirin: Convincing data supporting ribavirin treatment for severe RSV infection are lacking, and 
its toxicity remains a concern. Therefore, ribavirin is not recommended in the current U.S. 
guidelines.
71
 
 
New treatments: There are currently approximately 28 RSV vaccines and antibodies in preclinical 
development and another 17 in clinical development.
59,60
 Several new molecules have been 
identified for the treatment of RSV infection and are currently in (advanced) preclinical or clinical 
development.
72,73
 
 
Treatment for RV 
 
There are only few agents targeting the inhibition of the attachment of RV to the cell or uncoating 
viral RNA, and their clinical applicability is continuously questioned due to adverse events 
(pleconaril, vapendavir) or drug resistance (amantadine, rimantadne).
72,73
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Prednisolone: In two separate randomized trials oral corticosteroid, prednisolone, has been shown to 
decrease the time to the physician-confirmed relapse within the following year by 20-30% and to 
the initiation of asthma controller medication within the following 5 years by 30-40% in first-time 
wheezing children with RV etiology. These results point out, that early systemic anti-inflammatory 
control targeting the pre-existing and/or virus-induced airway inflammatory response could 
significantly affect the natural course of asthma.
74-77 
Interestingly, all wheezing children with high 
RV genome load treated with placebo developed a new physician-confirmed wheezing episode 
within 100 days and initiation of asthma control medication within 14 months.
76,77
 
 
In conclusion, according to our hypothesis regarding the various entities of bronchiolitis, we 
emphasize that effective treatment of bronchiolitis should be administered on a more personalized 
base than currently in practise and include various viral etiological factors. We do believe that 
existing treatment methods (beta2-agonists and corticosteroids) can be effective given the 
assumption that they are intended for a distinct (RV-affected) high-risk group of patients. However, 
there is an urgent and unmet need for n w guidelines which would recognize this discrepancy and 
for clinicians to understand that there is no more "common bronchiolitis". 
 
Long-term sequela 
 
Severe acute bronchiolitis experienced early in childhood is associated with an increased risk of 
asthma that may persist into early adulthood.
1
 It remains to be elucidated whether bronchiolitis is 
the cause of lung injury that results in subsequent wheezing episodes and asthma development or if 
there is an inherent predisposition to both acute bronchiolitis and latter asthma, with bronchiolitis 
being an early marker of this predisposition. Regardless of possible underlying lung morbidity, the 
major viral causes of acute bronchiolitis/first wheeze, RSV and RV, seem to have a different course 
in post-bronchiolitis asthma sequela.  
 
Several observational studies have reported an association between RSV-bronchiolitis and 
subsequent asthma development. For example, according to a population-based study (n=476) from 
Tucson, Arizona, and a birth cohort study (n=150) from Australia RSV-induced lower respiratory 
infection/bronchiolitis during early life is modestly associated with recurrent wheezing/doctor 
diagnosed asthma at school-age (odds ratio 2.5-4.3) but not with atopy.
78,79
 Similar numbers have 
also been found in preterm infants.
80
 Only a small cohort study from Sweden has shown an 
association between RSV-bronchiolitis and later allergic sensitization as well as asthma; by the age 
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18, 41% of the RSV children were allergic and 39% had asthma compared to the 17% and 9% in the 
control group, respectively.
81
 
 
To address the potential causality between RSV infection and subsequent asthma, prospective 
studies with RSV-immunoprophylaxis have been performed. Two recent randomized controlled 
trials showed that in preterm infants palivizumab, an anti-RSV monoclonal antibody, decreased the 
parent-reported recurrent wheeze, but similar incidence of physician diagnosed asthma at age 6 
years was found.
82,83
 Long-term effects of RSV prophylaxis appear less likely in infants with atopic 
family history.
60
 These results clearly indicate that RSV-infection is not causal to the asthma or 
atopy development. One potential explanation for these results is that children with RSV infection 
and subsequent asthma development may share common genetic vulnerability and/or environmental 
exposures that predispose them to both diseases.
84
 
 
In contrast to RSV bronchiolitis, atopy has been clearly associated with childhood asthma 
development after RV-induced early wheezing. High risk (parental atopy or asthma) birth cohort 
studies from Wisconsin, US, and Australia have shown that young children suffering from RV-
induced wheezing episodes are at high risk of school-age asthma (odds ratio up to, RV vs. RSV, 9.8 
vs 2.6).
85-87
 The risk is especially high if children were sensitizated at an age younger than 2 
years.
85,87
 A recent study on hospitalized children show similar results: RV-induced severe first 
wheezing episode at an age less than 2 years was a risk factor (odds ratio 5.0) for atopic asthma at 
school-age along with early sensitization and eczema (odds ratio 12 and 4.8, respectively) while 
RSV was associated with neither atopic nor non-atopic asthma.
7
 Therefore, data from these high-
risk birth cohorts suggest that atopic airways have an increased susceptibility for asthma 
development after RV-induced bronchiolitis. 
 
Primary and secondary prevention strategies of asthma 
 
The primary prevention strategies of asthma aim at reducing the incidence of the disease by 
identifying the individuals at risk and reducing their exposure to the potential risk factors. First, the 
hygiene hypothesis evolved to cover the environmental microbial burden in general.
88,89
 However, 
due to recent findings the scope of the hygiene hypothesis has enlarged to to cover the 
environmental biodiversity in general. Thus, rapid urbanization, pollution and climate change, all 
leading to the loss of biodiversity, promote chronic noncommunicable illnesses such as asthma, 
allergies, diabetes, obesity and cancer,
90-92
 where as frequent contact with animal lipopolysaccarides 
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present in all we eat, touch and breath prevent atopy, allergic rhinitis and sometimes asthma.
90,92
 
Second, conditions during preganancy are important. Maternal omega-3 long-chain polyunsaturated 
fatty acid (n-3 LCPUFA) and vitamin D supplementation in the third trimester of pregnancy may 
reduce the risk of persistent wheeze/asthma and respiratory infections in offspring (Fig 5).
93,94 
 
Secondary prevention strategies of asthma aim at avoiding the development of allergic 
disease/asthma in already sensitized or wheezing subjects.
95
 Thus far, allergen immunotherapy 
remains as the only treatment available for modifying the course of allergic disease.
96
 However, 
although in a recent study grass pollen immunotherapy was shown to reduce asthma-like symptoms 
in children, it did not decrease the development of asthma.
97
 Interestingly though, a systemic anti-
inflammatory treatment of the first RV-induced severe wheezing episode markedly decreased the 
subsequent risk for asthma (Fig. 5).(See treatment chapter).
74-77 
Also, a year-round and preseasonal 
treatment with omalizumab has ben shown to eliminate the seasonal peaks in asthma exacerbations, 
most of which are associated with RV infection.
98
 In addition to the reduction of allergic 
inflammation by preventing IgE binding to its receptor, omalizumab also enhances the IFN-γ 
response.
99
 Thus, it has been argued that omalizumab may improve the antiviral responses. RSV 
immunoprophylaxis with palivizumab has also been shown to reduce recurrent wheezing (see 
treatment and long-term sequela chapters).
60,70,82,83
 In the development of RV vaccine, promising 
results have been seen with a cross-reactive recombinant capsid protein in a mouse model.
14 
 
 
Non-specific antiviral approaches to reduce asthma include strategies aiming at enhancing the 
patient’s resistance to multiple respiratory viruses through administration of interferons or other 
immunostimulatory molecules.
72,73 
Strategies (microbial and others) to promote healthy epithelial 
barrier and the development of mucosal immune responses that can better resist viral infection 
might also help in preventing the development of asthma, as well as bacterial lysates, which may 
reduce the recurrent wheezing by increasing antiviral activity.
100
 However, the level of evidence 
still remains to be low.  
 
Going forward, it will be important to identify the patients at high risk for asthma and to find the 
specific primary and secondary prevention strategies for each individual patient (Fig. 5), e.g. 
sensitization, eczema and the first severe wheeze caused by RV appear to predict atopic asthma, 
while the first severe wheeze before 1-year-age, RV/RSV negative etiology and/or association with 
parental smoking appear predict nonatopic asthma.
7
 In conclusion, these new insights into viral 
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virulence, personal risk factors (genetics, allergy, and antiviral immunity) and environmental 
exposures (farm, urban, microbes and nutrition) provide hope that in future we might be able to 
reduce the occurence of childhood asthma (Fig. 5).  
 
Summary 
Clinically and pathophysiologically three main clusters of patiens can be identified among children 
suffering from severe bronchiolitis/first wheezing episode (Fig. 6): 1) RSV-induced bronchiolitis is 
characterized by young age of the patient and mechanical obstruction of the airways due to mucus 
and cell debris. For the treatment of RSV-induced bronchiolitis there is a prophylactic RSV-specific 
monoclonal antibody available that decreases the risk of recurrent wheezing. 2) RV-induced 
wheezing is associated with atopic predisposition and high risk for asthma, which may be reversed 
with systemic corticosteroid in patients with severe first episode. RV susceptibility, thus, serves as 
an important early marker for asthma prone children. 3) Wheeze due to other viruses are likely to be 
less frequent and severe. Clinically, it is important to distinguish between these three partially 
overlapping patient groups, as they are likely to respond to different treatments. The first severe 
episode of bronchiolitis or wheezing in a less than 2-year-old child appears to be a critical event and 
an important opportunity for designing secondary prevention strategies for asthma. Thus, 
bronchiolitis cannot simply be diagnosed using a certain cut-off age, butinstead, viral etiology 
should be used as the differentiating factor. For nomenclature, we suggest that there is an RSV-
induced bronchiolitis and an RV-induced first wheezing episode to better distinguish these 
conditions. 
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Legends to the figures 
 
Figure 1. The frequency of viral etiologic agents according to the age of the hospitalized patients 
with the first episode of bronchiolitis or wheezing. Viral diagnostics were based on PCR (including 
rhinovirus C species) except for human bocavirus which was based on serology. RSV, respiratory 
syncytial virus; RV, rhinovirus; BoV, human bocavirus 1; MPV, metapneumovirus; PIV, 
parainfluenza virus; AdV, adenovirus; CoV, coronavirus; Flu, Influenza.
8-10
 
 
Figure 2. Signs of bronchiolitis. The classic clinical presentation of bronchiolitis starts with 
symptoms of  viral upper respiratory infection. Lower respiratory tract symptoms including 
persistent cough, tachypnoea and increased work of breathing (as shown by intercostal retractions, 
use of accessory muscles, grunting or nasal flaring) later follow. The latter symptoms may progress 
to severe hypoxemia and cyanosis. RSV, respiratory syncytial virus; RV, rhinovirus 
 
Figure 3. Interactions between airway bacteria and virus in disease severity. The environment 
shapes the bacterial composition from early on and either as a consequence of this or a direct effect 
whether RSV and RV are prevalent. Interactions between the two in bronchiolitis episodes may 
determine the severity. 
 
Figure 4. Pathogenesis of respiratory syncytial virus (A) and rhinovirus infection (B) in the airway 
epithelial cells of healthy children and those at risk. CDHR3, Cadherin related family member 3; 
DC, dendritic cell; Eos, eosinophil; IFN, interferon; Ig, immunoglobulin; IL, interleukin; ILC, 
innate lymphoid cell; MDA, melanoma differentiation-associated protein; moDC, monocyte-
derived dendritic cells; NK, natural killer cell; RIG, Retinoic acid inducible gene; RSV, respiratory 
syncytial virus; RV, rhinovirus; TCE3, third T-cell receptor; Th, T helper cell; TLR, toll-like 
receptor; TSLP, Thymic stromal lymphopoietin. 
 
Figure 5. Major factors influencing asthma risk in young children suffering from bronchiolitis. RV, 
rhinovirus; RSV, respiratory syncytial virus; n-3 LCPUFA, n-3 (omega-3) long-chain 
polyunsaturated fatty acids. 
 
Figure 6. Main entities of bronchiolitis. It is important to distinguish these patient groups since they 
are likely to respond to different treatments. Also, the first episode of severe bronchiolitis or 
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wheezing in under 2-year-old children appears to be a critical event and an opportunity for 
designing secondary prevention strategies for asthma. MoAb, monoclonal antibody; OCS, oral 
corticosteroid; Th, T helper cell. 
Page 65 of 71 Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
RSV
RV
GENETICSETIOLOGY
17q polymorphisms
Common 
asthma risk 
genes/polymorphisms
RISK/PROTECTION CLINICAL COURSE
RISK FACTORS
 FOR SEVERE
ILLNESS 
PROTECTIVE
FACTORS
CLINICAL PICTURE 
OF DYSPNEA
TREATMENT
OPTIONS
OUTCOME
AT SCHOOL-AGE
• epithelial barrier 
  damage 
• early 
  sensitization 
• exposure 
  to allergens
• ”asthma-like” 
• acute wheezing 
• T helper 2 characteristics 
• ”older” age
Treatment: 
severe wheezing 
likely responds 
to oral corticosteroids
Atopic asthma
30–80%
• prematurity 
• young age 
• chronic illness 
• exposure
  to smoking
• noisy breathing 
• crackles
• mucousness 
• ”younger” age
Treatment: 
supportive
Recurrent 
wheezing 
10–30%
Prevention: 
ICS and omalizumab 
are likely effective
Prevention: 
palivizumab likely 
effective 
• healthy life-style
  (healthy nutrition,
  exercise, outdoor 
  activities) 
• diverse personal 
  microbiome 
• environmental 
  biodiversity 
• contact 
  with animal 
  and farm dust
Page 66 of 71Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 1  
 
87x68mm (300 x 300 DPI)  
 
 
Page 67 of 71 Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 2  
 
104x72mm (300 x 300 DPI)  
 
 
Page 68 of 71Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 3  
 
98x66mm (300 x 300 DPI)  
 
 
Page 69 of 71 Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 4  
 
197x251mm (300 x 300 DPI)  
 
 
Page 70 of 71Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 5  
 
103x71mm (300 x 300 DPI)  
 
 
Page 71 of 71 Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Fig. 6  
 
87x69mm (300 x 300 DPI)  
 
 
Page 72 of 71Allergy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
